A detailed history of Parametrica Management LTD transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Parametrica Management LTD holds 131,590 shares of IOVA stock, worth $1.02 Million. This represents 2.81% of its overall portfolio holdings.

Number of Shares
131,590
Previous 320,276 58.91%
Holding current value
$1.02 Million
Previous $2.6 Million 25.09%
% of portfolio
2.81%
Previous 4.28%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$7.59 - $17.47 $1.43 Million - $3.3 Million
-188,686 Reduced 58.91%
131,590 $1.95 Million
Q4 2023

Feb 02, 2024

BUY
$3.3 - $8.89 $742,090 - $2 Million
224,876 Added 235.72%
320,276 $2.6 Million
Q3 2023

Oct 31, 2023

SELL
$4.44 - $8.79 $4,884 - $9,668
-1,100 Reduced 1.14%
95,400 $434,000
Q2 2023

Aug 02, 2023

BUY
$5.36 - $9.06 $256,208 - $433,068
47,800 Added 98.15%
96,500 $679,000
Q1 2023

May 09, 2023

BUY
$5.53 - $8.22 $4,424 - $6,576
800 Added 1.67%
48,700 $297,000
Q4 2022

Feb 07, 2023

SELL
$5.62 - $10.0 $262,735 - $467,500
-46,750 Reduced 49.39%
47,900 $306,000
Q3 2022

Nov 02, 2022

SELL
$9.53 - $13.11 $202,226 - $278,194
-21,220 Reduced 18.31%
94,650 $907,000
Q2 2022

Jul 22, 2022

SELL
$6.38 - $18.33 $120,001 - $344,768
-18,809 Reduced 13.97%
115,870 $1.27 Million
Q1 2022

May 10, 2022

SELL
$12.38 - $19.1 $179,534 - $276,988
-14,502 Reduced 9.72%
134,679 $2.24 Million
Q4 2021

Feb 15, 2022

BUY
$16.55 - $27.63 $46,654 - $77,888
2,819 Added 1.93%
149,181 $2.85 Million
Q3 2021

Nov 12, 2021

BUY
$20.35 - $26.63 $1.47 Million - $1.92 Million
72,087 Added 97.05%
146,362 $3.61 Million
Q2 2021

Aug 13, 2021

BUY
$16.33 - $33.07 $1.21 Million - $2.46 Million
74,275 New
74,275 $1.93 Million
Q3 2020

Nov 13, 2020

SELL
$27.75 - $36.3 $242,923 - $317,770
-8,754 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$27.21 - $41.0 $238,196 - $358,914
8,754 New
8,754 $240,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.22B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Parametrica Management LTD Portfolio

Follow Parametrica Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parametrica Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Parametrica Management LTD with notifications on news.